<DOC>
	<DOCNO>NCT01383421</DOCNO>
	<brief_summary>Post-marketing observational study determine effectiveness patient satisfaction adalimumab treatment patient Rheumatoid Arthritis relation utilization Patient Support Program ( PSP ) .</brief_summary>
	<brief_title>Observational Study Research Effectiveness Adalimumab Treatment Conjunction With Utilization Patient Support Program ( PSP )</brief_title>
	<detailed_description>This study non-confirmatory study explore describe effectiveness adalimumab Rheumatoid Arthritis ( RA ) treatment course patient satisfaction time context utilization Patient Support Program ( PSP ) . The main objective examine effectiveness adalimumab treatment respect PSPs mean Health Assessment Questionnaire Disability Index ( HAQ-DI ) , Disease Activity Score ( DAS28 ) result , European League Against Rheumatism ( EULAR ) response criterion , well evaluate contribution PSP disease control , treatment continuation time , patient 's satisfaction , PSP utilization .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Male female age least 18 year newly prescribe adalimumab therapy accord local product label , first dose correspond Enrollment/Baseline visit . Patient diagnosis moderate severe Rheumatoid Arthritis ( RA ) , insufficient response one DiseaseModifying Antirheumatic Drugs ( DMARDs ) , prescription adalimumab accord local regulation . Patients evaluated tuberculosis ( TB ) exposure/risk factor active latent TB ( per local requirement accord local product label ) . Patients must able willing provide write authorization disclose use personal health information ( informed consent applicable ) comply requirement study protocol well agree data collect provided AbbVie . Patients enrol treated accordance local adalimumab product label . Patients treat &gt; 1 prior biologic Diseasemodifying Antirheumatic Drug ( DMARD ) Rheumatoid Arthritis ( RA ) . Any prior treatment adalimumab prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Patient Support Program</keyword>
	<keyword>adalimumab</keyword>
</DOC>